An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction
About:
This article is published in International Braz J Urol.The article was published on 2010-02-01 and is currently open access. It has received 848 citations till now.read more
Citations
More filters
Journal ArticleDOI
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline
E. Ann Gormley,Deborah J. Lightner,Kathryn L. Burgio,Toby C. Chai,J. Quentin Clemens,Daniel J. Culkin,Anurag K. Das,Harris E. Foster,Harriette Miles Scarpero,Christopher Tessier,Sandip Prasan Vasavada +10 more
TL;DR: This guideline provides a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder and identifies first through third line treatments as well as non-FDA approved, rarely applicable and treatments that should not be offered.
Journal ArticleDOI
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment
TL;DR: This guideline amendment focused on four topic areas: mirabegron, peripheral tibial nerve stimulation, sacral neuromodulation and BTX-A.
Journal ArticleDOI
An International Urogynecological Association (IUGA) / International Continence Society (ICS) Joint Report on the Terminology for Female Pelvic Organ Prolapse (POP)
Bernard T. Haylen,Christopher G. Maher,Matthew D. Barber,Sérgio Camargo,Vani Dandolu,Alex Digesu,Howard B. Goldman,Martin Huser,Alfredo L. Milani,Paul A. Moran,Gabriel N. Schaer,Mariella I. J. Withagen +11 more
TL;DR: The terminology for female pelvic floor prolapse (POP) should be defined and organized in a clinically‐based consensus Report.
Journal ArticleDOI
Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review
TL;DR: Current evidence demonstrates that the substantial economic burden of UUI to patients and society is demonstrated and will increase markedly as the population ages.
Journal ArticleDOI
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
Victor W. Nitti,Roger R. Dmochowski,Sender Herschorn,Peter K. Sand,Catherine Thompson,Christopher Nardo,Xiaohong Yan,Cornelia Haag-Molkenteller +7 more
TL;DR: OnabotulinumtoxinA 100 U showed significant, clinically relevant improvement in all overactive bladder symptoms and health related quality of life in patients inadequately treated with anticholinergics and was well tolerated.